High-Dose Influenza Vaccine and Its Impact on Alzheimer’s Risk in Seniors
Dennis Lenz
(Symbolbild). For individuals aged 65 and older, the annual influenza vaccine is available in two strengths that differ solely in the antigen content. An evaluation of nearly 200,000 seniors has compared the incidence of Alzheimer’s dementia in both groups. The difference in outcomes between the standard and high-dose vaccines was more pronounced than previous research suggested. The data originates from the United States, and the underlying vaccination recommendation is similarly applicable in Germany.
(Photo: © Forschung und Wissen)
A flu vaccine administered millions of times each autumn in Germany may serve as a possible protective factor for the aging brain. A research team analyzed the data of nearly 200,000 individuals aged 65 and older, directly comparing two variants of the same vaccine. Both differ exclusively in their antigen content, and the gap between the groups was notably greater than previously indicated by available data.
The Alzheimer’s disease is the most common form of dementia, affecting an estimated 1.4 to 1.8 million people in Germany, with around 70% of all dementia cases attributed to it. Characteristic changes include the accumulation of beta-amyloid proteins between nerve cells and tangles of misfolded tau proteins inside cells. These alterations often begin 15 to 20 years before the first memory gaps appear, sequentially destroying synapses and causing brain regions to shrink. For a long time, this protein cascade was considered almost a complete explanation for the disease. However, recent studies highlight the role of chronic inflammation in neural tissue progression. As the immune system weakens with age, the relationship between infections, vaccination, and Alzheimer’s is now under scrutiny in significant data analyses, shifting focus toward long-established routine measures.
The study centers on not a newly developed drug but an influenza vaccine already authorized for years. For those aged 65 and older, a high-dose version exists, containing four times the antigen amount to elicit a stronger antibody response. A research team from Houston evaluated whether these two formulations differed in the later onset of Alzheimer’s dementia, using anonymized health insurance and billing data from nearly 200,000 seniors who received either the high-dose or standard vaccine and were observed over several years. Newly diagnosed Alzheimer’s dementia was tracked through medical diagnosis codes and typical anti-dementia prescriptions. The results published in the journal Neurology were more pronounced than expected, shifting the debate towards vaccinations as a potential component in dementia prevention.
Why Vaccine Dosage Matters for Seniors
As individuals age, the immune system’s potency diminishes in a process known as immunosenescence. T-cells become slower to react, the immune memory becomes patchy, and antibody titers following vaccination are lower compared to younger adults. This is precisely why a high-dose influenza vaccine is available for the annual flu season, containing four times the antigen amount of regular vaccines. In the United States, this variant is recommended for all individuals aged 65 and older. In Germany, the Standing Vaccination Commission also advises people aged 60 and above to opt for a high-dose preparation or, alternatively, a vaccine enhanced with the MF59 adjuvant, with statutory health insurance covering the costs. It has long been demonstrated that vaccines provide differing levels of protection based on dosage, particularly against severe flu cases. Whether this difference also translates to the brain remained unclear until now.
Close to 200,000 Seniors Compared
The analysis relies on a substantial cohort of insurance holders aged 65 and above, differing in one key respect: one part received the high-dose vaccine, while the other received the standard dose, primarily due to regional availability issues. This supply gap created a comparison situation that is otherwise challenging to establish. According to UTHealth Houston, a standard-dose flu shot was already associated with approximately a 40% reduced risk of Alzheimer’s. The distinction was even clearer in the high-dose variant, demonstrating an approximate 55% relative risk reduction. This protective effect was particularly notable among women. However, the authors caution that this is an observational study, and a causal relationship has not been proven.
Potential Mechanisms Behind the Effect
How an influenza vaccine may affect the brain remains largely unclarified. Several pathways are being discussed. For one, vaccine protection can prevent severe flu events accompanied by systemic inflammatory responses, often leading to measurable cognitive decline in older individuals. Additionally, vaccines may exert non-specific effects on the innate immune system, shifting the microglia, the brain’s scavenger cells, into a less harmful activation state. A higher antigen dose could amplify both effects, explaining why the curves diverge between the groups. Similar observations exist for other vaccines, as seen with shingles vaccinations, which not only reduce disease risk but also influence the progression of existing dementia. Ultimately, determining whether the effect comes directly from the vaccine or if vaccinated individuals differ in other characteristics will require randomized studies to conclusively resolve.
Neurology, Risk of Alzheimer Dementia After High-Dose vs Standard-Dose Influenza Vaccination; doi:10.1212/WNL.0000000000214782
